PRESS RELEASE published on 01/13/2025 at 18:00, 1 year 8 months ago Informatie met betrekking tot het Totaal Aantal Stemrechten (Noemer) volgend op Atlas Conversie-Notificatie Atlas Special Opportunities, LLC convertit 4 obligations convertibles en Oxurion pour une augmentation de capital de 100 000 EUR, soutenant le développement de médicaments pour préserver la vision des personnes âgées Obligations Convertibles Augmentation De Capital Atlas Special Opportunities Médicaments Innovants Oxurion
BRIEF published on 01/06/2025 at 18:05, 1 year 8 months ago Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Transparency Biopharmaceutical Shareholding Atlas Special Opportunities Oxurion
BRIEF published on 01/06/2025 at 18:05, 1 year 8 months ago Oxurion reçoit une notification de transparence de la part d'Atlas Special Opportunities LLC Actionnariat Transparence Biopharmaceutique Oxurion Opportunités Spéciales Atlas
PRESS RELEASE published on 01/06/2025 at 18:00, 1 year 8 months ago Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Oxurion NV received a transparency notification from Atlas Special Opportunities, LLC revealing a stake above 15% threshold due to purchase of voting securities Transparency Notification Biopharmaceutical Atlas Special Opportunities Ophthalmic Therapies Oxurion NV
PRESS RELEASE published on 01/06/2025 at 18:00, 1 year 8 months ago Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities LLC Oxurion NV receives transparency notification from Atlas Special Opportunities LLC regarding ownership of 624,817 shares, exceeding the 15% threshold Transparency Notification Share Ownership Atlas Special Opportunities LLC Oxurion NV Ophthalmological Therapies
BRIEF published on 01/03/2025 at 18:05, 1 year 9 months ago Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Shares Transparency Biopharmaceutical Atlas Special Opportunities Oxurion
BRIEF published on 01/03/2025 at 18:05, 1 year 9 months ago Oxurion reçoit une notification de transparence de la part d'Atlas Special Opportunities LLC Actions Transparence Biopharmaceutique Oxurion Opportunités Spéciales Atlas
PRESS RELEASE published on 01/03/2025 at 18:00, 1 year 9 months ago Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Oxurion NV received a transparency notification under Belgian Transparency legislation from Atlas Special Opportunities, LLC, regarding the sale of voting securities Transparency Notification Atlas Special Opportunities LLC Oxurion NV Belgian Legislation Retinal Disease Therapy
PRESS RELEASE published on 01/03/2025 at 18:00, 1 year 9 months ago Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities LLC Oxurion NV announces receipt of transparency notification regarding shareholding. Bio-pharmaceutical company developing ophthalmological therapies. Refer to website for more details Transparency Notification Shareholding Belgium Oxurion NV Ophthalmological Therapies
BRIEF published on 12/31/2024 at 18:05, 1 year 9 months ago Oxurion reporte une transaction stratégique en raison de discussions en cours Report Transaction Stratégique Oxurion Discussions Financières Louvain
Published on 10/05/2026 at 22:30, 8 hours 8 minutes ago EV Nickel Announces Formation of Wholly Owned Subsidiary to Advance Nickel Bioleaching Technology and Canadian Nickel Supply Chain
Published on 10/05/2026 at 14:45, 15 hours 53 minutes ago NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives
Published on 10/05/2026 at 14:30, 16 hours 8 minutes ago Hillcrest and Equipmake Expand Partnership Talks to Include Commercial Licensing of ZVS Technology
Published on 10/05/2026 at 14:30, 16 hours 8 minutes ago Solitario CEO to Present at John Tumazos Very Independent Research, LLC
Published on 10/05/2026 at 14:00, 16 hours 38 minutes ago Tectonic Metals Appoints Eduard Epshtein as CFO, Bolstering Executive Team for Next Stage of Growth
Published on 10/06/2026 at 03:00, 3 hours 38 minutes ago Qupital Unveils World’s First AI-Driven On-Chain E-Commerce Lending Protocol, Accelerating Web3 Global Trade Finance
Published on 10/05/2026 at 22:25, 8 hours 12 minutes ago LumApps Named a Leader in 2026 Gartner® Magic Quadrant™ for Intranet Packaged Solutions
Published on 10/05/2026 at 22:05, 8 hours 32 minutes ago AMPERA SUBMITS COMPREHENSIVE ENGAGEMENT PLAN TO THE U.S. NUCLEAR REGULATORY COMMISSION
Published on 10/05/2026 at 21:10, 9 hours 28 minutes ago Shelly Group Board of Directors considers EUR 70.00 offer price fair and supports Schneider Electric’s voluntary public tender offer
Published on 10/05/2026 at 21:05, 9 hours 32 minutes ago EQS-Adhoc: Shelly Group SE: Board of Directors with positive opinion on the registered voluntary public tender offer by Schneider Electric SE
Published on 10/05/2026 at 22:12, 8 hours 26 minutes ago AXA - Elimination of the dilutive impact of Shareplan 2026
Published on 10/05/2026 at 22:12, 8 hours 26 minutes ago AXA - Elimination de l'effet dilutif de l'opération Shareplan 2026
Published on 10/05/2026 at 18:13, 12 hours 25 minutes ago Disclosure of shares outstanding and voting rights - 05.10.2026
Published on 10/05/2026 at 18:13, 12 hours 25 minutes ago Déclaration nombre d'actions et droits de vote - 05.10.2026
Published on 10/05/2026 at 18:00, 12 hours 38 minutes ago LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 30 septembre 2026
